Additional Diagnosis opportunities with the novel cardiac marker GPBB

Essen, 18.05.2010 – Diagenics International Corporation starts its first extensive study project in collaboration with its latest partner, the German Myocardial Infarction Research Institute (IHF).

The UPGRADE-protocol (Unified Protocol for GPBB Rapid ACS Diagnosis Enhancement) will take place within the scope of the Chest Pain Unit Register. The register documents all consecutive patients that are included in a participating Chest Pain Unit (CPU). In the course of this the patient characteristics, the diagnosis carried out, timing, complications and the consequences for the patient are recorded. The CPU register currently comprises 50 participating study centers with a total of 4.100 patients. In addition to the CPU register the UPDGRADE study will include up to 3.000 new patients.

The aim of the UPGRADE study is the systematic and uniform statistical analysis of the parameter glycogen phosphorylase isoenzyme BB (GPBB) for the detection of cardiac tissue damage in the diagnosis of acute coronary syndromes (ACS) patented by Diagenics.
Whether GPBB can serve the early decision making as an early marker of a cell damage and thus improve diagnostic and therapeutic approaches contributes to the subject of this study.
Another objective of this study is to compare the new parameter GPBB as a biochemical marker with the established marker Troponin in order to develop clinical practice recommendations.

The results of this study are expected in the fourth quarter of 2010.

DIAGENICS is a biopharmaceutical company located in Woburn (Boston), MA (USA) with its European headquarters in Essen, Germany. Our unique business model strives to build a Bridge from Science to Business™.

In this way we aspire to a leading position in the diagnostic field. We are currently focussing on the detection of heart infarction through a new and patented heartmarker.

DIAGENICS constantly observes scientific results and compares them with the needs of market and economy.

Thus, many promising projects are targeted, licensed and quickly developed until they are ready for the market. With DIACORDON™, DIAGENICS has already launched its first product line for the diagnosis of infarction. Besides the development of a sophisticated ACS biochip device DAGENICS plans to widen its supply with projects on stroke diagnosis.

Diagenics Produktions GmbH
Alfredstrasse 98
45131 Essen
Presscontact:
Marcel Marinov
m.marinov@diagenics.de

Tel: +49 (0)201 289 990 0
Fax: +49 (0)201 289 990 13

This release was published on openPR.